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1. Introduction 
Pulmonary hypertension (PH) is associated with increased morbidity and mortality and is 
an important prognostic factor in cardiac surgery. As the average age and associated co-
morbidities of cardiac surgical patients increase, the prevalence of PH is likely to rise. In this 
chapter, we will define PH, classify it on the basis of pathophysiological etiology, and 
suggest treatment therapies according to this classification. The importance of PH in cardiac 
surgery, its relationship to right ventricular dysfunction and preventive therapies will also 
be discussed. When applicable, we will draw from our clinical experience with PH to 
suggest strategies for the prevention of possible complications. 
2. Definition of pulmonary hypertension 
2.1 Hemodynamic parameters used in clinical settings 
There are several hemodynamic parameters used in defining PH (Table 1) (Gomez & 
Palazzo, 1998). These definitions have been used in various studies. 
2.2 Diagnosis in awake and anesthetized patients 
Pulmonary hypertension is usually diagnosed prior to cardiac surgery in awake patients. 
The diagnosis is obtained either directly by cardiac catheterization or indirectly by using 
Doppler signals from transesophageal echocardiography (TEE) and using Bernoulli’s 
equation. In the presence of tricuspid regurgitation, the simplified Bernoulli’s equation gives 
an estimation of the pressure gradient across the tricuspid valve (Fig. 1) (Denault et al., 
2010a). This pressure gradient is equal to the difference in systolic pressure between the 
right ventricle (RV) and the right atrium. Therefore, with the measurement of right atrial 
pressure (Pra), the estimation of systolic right ventricular pressure (Prv) is possible. In the 
absence of right ventricular outflow tract obstruction (RVOTO) and pulmonic valve stenosis, 
systolic Prv represents a reliable estimation of the systolic pulmonary artery pressure 
(SPAP). 
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CI: cardiac index; CO: cardiac output; MAP: mean arterial pressure; PAOP: pulmonary artery occlusion 
pressure; SVRI: indexed systemic vascular resistance. Adapted from Gomez (Gomez & Palazzo, 1998). 
Table 1. Definitions of Pulmonary Hypertension Used in Clinical Settings 
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Fig. 1. (A) Estimation of right ventricular systolic pressure (systolic Prv or RVSP) using the 
pressure gradient (PG) obtained from tricuspid regurgitation (TR) and right atrial pressure 
(Pra). (B) Note that the RVSP is higher than the systolic pulmonary artery pressure (Ppa) 
due to a small gradient across the pulmonic valve. (EKG: electrocardiogram; V: velocity). 
With permission from Denault et al. (Denault et al., 2010a). 
2.3 Comparison of absolute and relative values in the assessment of pulmonary 
hypertension 
Following the induction of general anesthesia, a reduction in both the systemic and the 
pulmonary artery pressures is observed. Consequently, using absolute values of SPAP in 
defining PH would underestimate its severity. To address this issue, Robitaille et al. studied 
1557 patients undergoing cardiac surgery (Robitaille et al., 2006). In the 32 patients with 
preoperative PH, induction of general anesthesia resulted in a significant reduction in mean 
arterial pressure (MAP) and mean pulmonary artery pressure (MPAP) but the ratio of 
MAP/MPAP remained stable (Fig. 2). The normal value for this ratio is > 4, and lower 
values can be used to quantify the severity of PH. 
The relevance of the MAP/MPAP ratio was demonstrated after comparing its ability to 
estimate the probability of postoperative complications with the ability of other normally 
used hemodynamic parameters for this purpose (listed in Table 1). Values of the ratio 
obtained after induction of general anesthesia but before cardiopulmonary bypass (CPB) in 
1439 patients undergoing cardiac surgery showed similar trend when compared to other  
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Fig. 2. Changes in mean arterial pressure (MAP), mean pulmonary artery pressure (MPAP), 
and the MAP/MPAP ratio after the induction of anesthesia in 32 patients with preoperative 
pulmonary hypertension. No significant change in the MAP/MPAP ratio was observed (*p 
< 0.05). (Robitaille et al., 2006) 
hemodynamic parameters (Fig. 3). Furthermore, the ratio turned out to be the best predictor 
of perioperative complications, defined as death, need for intra-aortic balloon pump, cardiac 
arrest, or use of vasoactive support for more than 24 hours. 
An abnormal MAP/MPAP ratio was also recognized to be significantly correlated with 
abnormal systolic and/or diastolic cardiac function (Fig. 4) (Robitaille et al., 2006). The use 
of relative instead of absolute values to estimate PH is currently used in congenital 
cardiology (Therrien et al., 2001a; Therrien et al., 2001b). 
In summary, the evaluation and diagnostic of PH in cardiac surgical patients must be done 
using specific criteria. In awake patients, the absolute values can be used since they correlate 
well with outcomes. However, in patients under general anesthesia, the ratio of 
MAP/MPAP allows to screen for PH when systolic blood pressures are lower due to the 
anesthetic agents. 
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Fig. 3. Relationship between the estimated probability of hemodynamic complications and 
variables used in the evaluation of pulmonary hypertension: (A) systolic pulmonary artery 
pressure (SPAP), (B) mean pulmonary artery pressure (MPAP), (C) indexed pulmonary 
vascular resistance (PVRI), (D) systemic to pulmonary vascular resistance index ratio 
(SVRI/PVRI), (E) mean systemic to pulmonary pressure ratio (MAP/MPAP), and (F) 
transpulmonary gradient defined as MPAP - Wedge or pulmonary artery occlusion pressure 
(PAOP). For easier comparison, the scale of the x axis of the SVRI/PVRI and the 
MAP/MPAP are inverted. (n = number of patients). (Robitaille et al., 2006) 
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Fig. 4. Hemodynamic and transesophageal echocardiographic evaluation of a 46-year-old 
woman scheduled for aortic valve surgery. Despite a normal pulmonary artery pressure 
(Ppa) of 34/16 mmHg and pulmonary vascular resistance index (PVRI) at 286 dyn·s·cm-5·m-
2, this patient had an abnormal right ventricular diastolic filling pressure waveform 
characterized by a rapid upstroke (A) and reduced systolic (S) to diastolic (D) pulmonary 
(B) and hepatic (C) venous flows consistent with left and right ventricular diastolic 
dysfunction. In addition, a dilated right atrium and ventricle were present without 
significant tricuspid regurgitation in a mid-esophageal right ventricular view (D). The mean 
systemic to pulmonary pressure ratio (MAP/MPAP) was 65/23 or 2.8. (CI: cardiac index; 
Pa: arterial pressure; PCWP: pulmonary capillary wedge pressure; Pra: right atrial pressure; 
Prv: right ventricular pressure; RA: right atrium; RV: right ventricle; SVRI: systemic vascular 
resistance index). (Robitaille et al., 2006) 
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3. Classification of pulmonary hypertension based on pathophysiology and 
etiology 
The 2008 World Symposium on PH endorsed by The World Health Organization (WHO) 
proposed a classification system divided into 5 groups: 1) Pulmonary arterial hypertension, 2) 
PH owing to left heart disease, 3) PH owing to lung diseases and/or hypoxia, 4) Chronic 
thromboembolic PH, and 5) PH with unclear or multifactorial etiologies (Simonneau et al., 2009). 
In cardiac surgery, PH is more frequently classified as pre-capillary, capillary or post-
capillary, depending on the site where the underlying cause of PH is found. In this context, 
PH during cardiac surgery is typically post-capillary since the cause is mainly of left 
ventricular (LV) origin, past the pulmonary capillary bed. To confirm this diagnosis, 
pulmonary artery catheterization can be used to demonstrate an equal value for diastolic 
pulmonary artery pressure (DPAP) and pulmonary artery occlusion pressure (PAOP). When 
the cause for PH is at the pre-capillary or capillary level, in absence of tachycardia, DPAP is 
significantly higher than PAOP (Gomez & Palazzo, 1998). 
The causes underlying PH in cardiac surgery can be complex and may result from several 
mechanisms acting alone or in combination (Fig. 5). These mechanisms may exist before the 
operation or appear during or after the procedure. Exacerbation of PH may happen at any 
time during cardiac surgery, before, during or after CPB. Indeed, patients are at risk of LV 
failure at all times, especially after CPB when the reperfusion of the ischemic lungs can 
cause pulmonary reperfusion syndrome. Finally, PH can persist postoperatively secondary 
to a patient-prosthesis-mismatch (PPM) after mitral or aortic valve replacement. The 
treatment of PH is based on the identification of its etiology, whence the importance of 
distinguishing between the different pathophysiologies.  
 
 
Fig. 5. Major mechanisms of pulmonary hypertension in cardiac surgery. Other mechanisms 
may be operating at several levels: for instance, hypoxia (capillary) may lead to pulmonary 
hypertension, right ventricular systolic failure and, through interventricular interaction, left 
ventricular diastolic function (post-capillary). 
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3.1 Review of the factors involved 
The most important causes of PH in cardiac surgery, illustrated in Fig. 5, are classified 
according to their originating anatomical site: pre-capillary, capillary and post-capillary. 
3.1.1 Pre-capillary 
Pulmonary embolism 
Pulmonary embolism is an example of a pre-capillary PH. It may occur before, during or 
after CPB leading to the development or the exacerbation of PH. Thrombus, air and even 
carbon dioxide (Martineau et al., 2003) can cause pulmonary embolism. Pulmonary 
embolisms are rare in the immediate cardiac postoperative period. However, patients at risk 
include patients with predisposing factors to PH and patients with chronic thromboembolic 
pulmonary hypertension (CTEPH) (Fig. 6). The incidence of CTEPH is uncertain, but it 
represents a frequent cause of PH occurring in up to 4% of patients after an acute 
pulmonary embolism (Pengo et al., 2004; Tapson & Humbert, 2006). 
 
 
 
 
Fig. 6. Chronic pulmonary embolism. (A, B) Mid-esophageal ascending aorta (Ao) long-axis 
view in a 65-year-old woman with chronic pulmonary embolism shows the mobile clot 
adherent to the right pulmonary artery (RPA) wall. (LA: left atrium; LV: left ventricle). With 
permission from Denault et al. (Denault et al., 2010a). 
3.1.2 Capillary 
Cardiopulmonary bypass 
Pulmonary damage during cardiopulmonary bypass (CPB) is one of the important etiologies 
of PH in cardiac surgery. This is mainly due to the fact that the lungs are ischemic during 
CPB. The underlying mechanisms include 1) release of cytokines through endotoxin 
production (Downing & Edmunds, Jr., 1992), 2) complement activation and 3) ischemia 
reperfusion injury (Wan et al., 1997; Asimakopoulos et al., 1999) which leads to the 
production of free radicals, endothelin and prostacyclin derivatives with nitric oxide 
inhibition (Wan et al., 1997). The resulting systemic inflammatory response, pulmonary 
reperfusion syndrome as well as the transfusion of blood products may all exacerbate PH 
(Fig. 7) (Lesage et al., 1966; Kaul & Fields, 2000). 
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76-year-old woman after AVR 
Fig. 7. Unexpected pulmonary hypertension upon weaning from cardiopulmonary bypass 
(CPB) in a 76-year-old woman after aortic valve replacement (AVR). The CPB duration was 
71 minutes. A significant increase in pulmonary arterial pressure in relation to the systemic 
arterial pressure was observed as the patient was weaned from CPB. No mechanical causes 
were found. 
During CPB, blood is exposed to an artificial surface for oxygenation before it is sent back 
into the systemic circulation. This is associated with an inflammatory reaction secondary to 
endothelial activation, activation of the complement cascade, neutrophils, thrombin and 
platelets. Since the heart and lungs do not receive blood during CPB, cardioplegia solutions 
are used to preserve heart function, however, no specific protection is undertaken for the 
pulmonary circulation. In some patients, this may result in pulmonary reperfusion 
syndrome associated with postoperative endothelial dysfunction and PH or in post-CPB 
respiratory distress syndrome. The latter phenomenon, similar to the respiratory distress 
syndrome in adults, is characterized by an increased capillary permeability leading to a 
reduction in oxygenation, increased alveolar-arterial gradient, decreased lung compliance, 
increased pulmonary vascular resistance (PVR), and exacerbation of preoperative PH. 
Activation of the endothelin system during CPB increases endothelin ET-1 concentrations 
and correlates with CPB duration, severity of PH and post-CPB myocardial dysfunction. For 
this reason, CPB duration plays a major role in the incidence of mortality in cardiac surgery. 
Post-CPB PH can lead to RV dysfunction which, when severe, is fraught with a 44 to 86% 
mortality rate. 
Protamine 
The administration of protamine can induce catastrophic pulmonary vasoconstriction in up 
to 1.8% of patients (Ocal et al., 2005). Protamine is administered in CPB to neutralize the 
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anti-clotting effects of heparin and has the capacity to activate the complement cascade. 
Thus, when given at the end of CPB, it can induce PH associated with adverse 
hemodynamic responses that range from minor perturbations to cardiovascular collapse, 
and may occur in three forms: systemic hypotension, anaphylactoid reaction and 
catastrophic PH (Viaro et al., 2002). The mechanism of protamine-induced PH is thought to 
be caused by an imbalance of vasoconstrictors and vasodilators leading to a reduction in 
nitric oxide release from the pulmonary vasculature (Viaro et al., 2002). 
Lung diseases and/or hypoxia 
In this category, the predominant cause of PH is alveolar hypoxia as a result of impaired 
control of breathing or lung disease. 
Lung volumes exert a differential effect on the resistance of intra- and extra-alveolar vessels, 
which accounts for the unique U-shaped relationship between lung volume and pulmonary 
vascular resistance (PVR) (Fig. 8). At functional residual capacity (FRC), PVR is minimal but 
increases at large or total lung capacity (TLC) and small lung volumes. Clinically, this may 
be observed when hyperinflation of the lungs greatly increases PVR (Fischer et al., 2003).  
 
 
Fig. 8. Relationship between lung volume and pulmonary vascular resistance (PVR). At 
functional residual capacity (FRC) PVR is minimal and increases at large or total lung 
capacity (TLC) and residual volume decreases at small lung volumes. The differential effect 
on intra- and extra-alveolar vessels accounts for the U-shaped relationship of PVR and lung 
volume. Adapted from Fischer et al. (Fischer et al., 2003). 
Changes in cardiac output (CO), airway pressure, and gravity may affect the pulmonary 
circulation. Therefore, patients with PH already have a restricted pulmonary circulation and 
increases in oxygen demand may further worsen PH and lead to right heart failure. 
Application of high levels of positive end-expiratory pressure (PEEP) may narrow 
capillaries in well-ventilated lung areas (intra-alveolar) and divert blood flow to less well-
ventilated or non-ventilated areas (extra-alveolar). Thus, intrapulmonary shunts may result 
in desaturation of mixed venous blood, potentially leading to hypoxia. 
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Hypoxia may also be caused by right-to-left intracardiac shunting through a patent foramen 
ovale (PFO) or a congenital heart defect. Pulmonary hypertension can lead to RV 
dysfunction causing increased pressure in the right atrium. In turn, the increase in Pra may 
result in opening of a PFO, present in 20-30% of the general population (Sukernik et al., 
2001), increasing the severity of hypoxia. In contrast to systemic arteries, pulmonary vessels 
constrict with hypoxia (Euler-Liljestrand reflex) and dilate in the presence of hyperoxia 
(Fischer et al., 2003), which explains the exacerbation of PH with hypoxia. 
Hypercapnia can occur especially in the case of acute lung injury during or after the 
procedure. The increase in partial pressure of carbon dioxide (PCO2) will cause 
vasoconstriction and therefore worsen PH. 
Increases in CO distend open vessels and recruit previously closed vessels so that when the 
cross-sectional area of pulmonary circulation increases, PVR decreases. 
Mechanical compression of pulmonary vessels is transmitted to the surrounding cardiac 
pressure and contributes to increase PAP. Hemothorax or tension pneumothorax may be 
responsible for an elevation in intrathoracic pressure. 
In addition, gravity influences blood flow in the pulmonary circulation. Both regional blood 
flow and ventilation are greater in the dependent areas of the lung (intra-alveolar). Hence, 
the relationship between alveolar and hydrostatic pressure bears important clinical 
consequences. 
Multiple molecular pathways are involved in the regulation of PVR, namely nitric oxide, 
prostacyclin, endothelin-1 and serotonin pathways (Humbert et al., 2004). Nitric oxide and 
prostacyclin are endogenous vasodilators produced in the pulmonary vascular 
endothelium. Endothelin-1 is an endogenous vasoconstrictor peptide secreted by the 
vascular endothelium and plays a role in pulmonary vasoconstriction and vascular smooth 
muscle proliferation (McLaughlin & McGoon, 2006). The neurotransmitter serotonin and the 
serotonin receptor transporter are also involved in the regulation of pulmonary vascular 
tone. Therefore, an imbalance in these pathways may result in vasoconstriction and vascular 
remodelling, potentially leading to progressive pulmonary vascular disease. 
3.1.3 Post-capillary 
Left heart disease 
Left ventricular disease represents the most frequent cause of PH in cardiac surgery (Oudiz, 
2007). Left-sided dysfunction includes three distinct etiologies: systolic dysfunction, 
diastolic dysfunction, and valvular heart disease (mitral and/or aortic). Pre- or 
postoperative left-sided ventricular or valvular diseases may produce an increase in left 
atrial pressure, with passive backward transmission of the pressure leading to increased 
PAP. The elevation of PAP and PVR is due to either the increase of pulmonary artery 
vasomotor tone and/or pulmonary vascular remodeling (Delgado et al., 2005; Moraes et al., 
2000). 
Patient-prosthesis mismatch 
Aortic patient-protheis mismatch (PPM) through a reduction in coronary reserve would also 
contribute to postoperative PH (Bakhtiary et al., 2007) and persistent postoperative valvular 
gradients (Fig. 9). There is general agreement that the postoperative indexed effective orifice 
area (EOA) of the prosthesis being implanted should not be < 0.85 to 0.90 cm2/m2. Mitral 
PPM was recently described as another cause of residual postoperative PH. Magne et al.  
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Fig. 9. Patient-prosthesis aortic valve mismatch. A 71-year-old man with a body surface area 
of 1.89 m2 was re-operated for symptoms of severe aortic valve stenosis. He had an aortic 
vavle replacement (AVR) 4 years before with a Carbomedics 19 mm mechanical bileaflet 
prosthesis (non-indexed effective orifice area = 1.06 cm2). (A) The preoperative mean 
gradient was 41 mmHg although the intraoperative inspection of the prosthetic valve was 
completely normal. (B) Intraoperative view of an aortic root enlargement procedure in a 69-
year-old patient with a reduced aortic diameter requiring AVR. Courtesy of Dr. Michel 
Carrier. With permission from Denault et al. (Denault et al., 2010a). 
(Magne et al., 2007) studied 929 patients who underwent mitral valve replacement (MVR), 
following them up to 15 years. Mitral valve PPM was defined according to the indexed 
valve EOA as not clinically significant (EOA > 1.2 cm²/m²), moderate (1.2 cm²/m² ≥ EOA > 
0.9 cm²/m²), and severe (EOA  0.9 cm²/m²). Prevalence of moderate and severe PPM was 
69% and 9%, respectively. In addition, severe PPM was found to be associated with residual 
PH and a 3-fold increase in postoperative mortality after adjustment for other risk factors. 
This relevant new finding is currently absent from the majority of studies involving 
predictors of survival in mitral valve surgery. 
4. Treatment of pulmonary hypertension in cardiac surgery based on 
pathophysiology and etiology 
The approach to pharmacological and non-pharmacological treatment of PH will be directed 
towards the cause or the consequence of PH, as illustrated in Fig. 5. Most often, treatment of 
the underlying mechanism causing PH requires non-pharmacological approaches, while 
pharmacological approaches will usually be the solution for the treatment of persisting PH 
and its consequence, RV failure. 
4.1 Pharmacological and non-pharmacological approaches 
Therapeutic management of PH has dramatically improved in the last years, offering both 
relief from symptoms and prolonged survival. However, there is still no cure for this disease. 
Moreover, in presence of PH, the choice of the appropriate therapy should rely on evidence-
based medicine. By performing a Medline search using the keywords ‘randomized 
controlled trial’, ‘humans’, ‘adults’, ‘pulmonary hypertension’ and ‘English’, a total of 14 
articles in cardiac surgery were retrieved. These publications were then classified according 
to their levels of evidence (Sackett, 1989; Moher et al., 2001) and summarized in Table 2. 
Most of the studies reviewed were based on a small number of patients and had  
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CABG: coronary artery bypass graft; CO: cardiac output; CPB: cardiopulmonary bypass; iNO: inhaled 
nitric oxide; iPGI2: inhaled prostacyclin; MVR: mitral valve replacement; NO: nitric oxide; NTG: 
nitroglycerin; PAOP: pulmonary artery occlusion pressure; PGE1: prostaglandin E1; PGI2: prostacyclin; 
PH: pulmonary hypertension; RCT: randomized controlled trial; UK: United Kingdom; USA: United 
States of America. 
Table 2. Randomized Controlled Trial in the Treatment of Pulmonary Hypertension in 
Adult Cardiac Surgery 
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hemodynamic changes as their primary end-points. Various pharmacological agents were 
studied: inhaled prostacyclin I2 (iPGI2), inhaled nitric oxide (iNO), heparinase, protamine 
and intravenous vasodilators including prostaglandin E1 (PGE1), nitroglycerin (NTG), 
nitroprusside, milrinone, enoximone, dobutamine, oral sildenafil, beraprost and oxygen. 
Findings on pharmacological and non-pharmacological approaches for the treatment of PH 
in cardiac surgery will be discussed together in this section. 
4.1.1 Pre-capillary 
Pulmonary embolism  
Acute pulmonary embolism during cardiac surgery can lead to PH and, in some cases, 
evolve into CTEPH. Pulmonary thromboembolectomy, when surgically indicated, can help 
control PH and is currently the only curative treatment in patients with CTEPH (Jamieson & 
Nomura, 2000; Jamieson et al., 2003) (Fig. 6). In case of CTEPH, evaluation of the feasibility 
of surgery mainly depends on the location of the obstruction (central vs. more distal 
pulmonary arteries) (Dartevelle et al., 2004). Patients who are not candidates for surgery 
may also benefit from PH-specific medical therapy, however, the use of these medications in 
CTEPH requires further evaluation in randomized controlled trials (Jais et al., 2008; Rubin et 
al., 2006; Suntharalingam et al., 2008). 
The rationale for systemic anticoagulant therapy for chronic lung embolism in patients with 
PH may be justified by well-recognized risk factors for venous thromboembolism, such as 
heart failure, a sedentary lifestyle, and a thrombophilic predisposition (Bjornsson & 
Edwards, 1985). However, no data actually support anticoagulant therapy specifically in 
patients with PH. Warfarin has been evaluated in only two nonrandomized studies, one 
retrospective and the other prospective, involving a small number of patients (Fuster et al., 
1984; Rich et al., 1992). 
4.1.2 Capillary 
Cardiopulmonary bypass 
As discussed, CPB causes pulmonary damage during surgery through different 
mechanisms, potentially leading to PH but, more frequently, it contributes to the 
exacerbation of PH caused by other factors during the surgical procedure. In this context, 
patients can benefit from PH-specific medical therapy (Table 2) and prophylactic treatments 
for PH use in cardiac surgery, which will be discussed later in this chapter.  
In 62 patients with preoperative PH (PVR > 125 dyn·sec·cm-5 immediately before induction 
of anesthesia) Solina et al. (Solina et al., 2001) explored the dose-responsiveness of 10, 20, 30 
and 40 ppm of iNO administered upon termination of CPB in comparison to an intravenous 
bolus of 50 mg/kg of milrinone given 15 minutes before separation from CPB followed by a 
0.5 mg/kg/min regimen administered in the operating room thereafter. Treatment with 
iNO was associated with significant reductions in PVR at all doses but no improved benefit 
was observed for doses higher than 10 ppm. No significant difference was observed 
between iNO and milrinone in terms of reduction in PVR and inotropic requirement.  
The same team compared 20 and 40 ppm of iNO to the same dose of intravenous milrinone 
in 45 patients after cardiac surgery (Solina et al., 2000). Study drugs were administered upon 
termination of CPB for a 24h-period in the intensive care unit (ICU). The group receiving 20 
ppm iNO had a significantly higher MAP while the group receiving 40 ppm had higher 
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right ventricular ejection fraction (RVEF) on arrival in the ICU. The milrinone group 
required significantly more phenylephrine in the ICU with a trend towards higher heart 
rates. 
In a crossover study, Schmid et al. (Schmid et al., 1999) compared iNO, PGE1 and NTG in 14 
adult patients with severe PH (MPAP > 30 mmHg; PVR > 300 dyn·sec·cm-5) after cardiac 
surgery. The investigation was performed in the ICU within the first 24 h after the 
procedure. The generalization of results obtained from this study was limited, since it only 
included patients in stable postoperative circulatory conditions. However, in contrast to 
PGE1 and NTG, iNO decreased PVR without exerting concomitant systemic vasodilatory 
effects. In addition, iNO did not affect the right coronary perfusion pressure and increased 
oxygen transport. 
Protamine 
The administration of protamine can be associated with severe PH followed by RV failure. 
This condition requires immediate treatment. In coronary artery bypass graft (CABG) 
patients (n=3800), Ocal et al. (Ocal et al., 2005), two therapeutic approaches were compared 
for the treatment of the protamine reaction observed in 68 of them (1.8%). One group 
received iPGI2 and the other intravenous NTG in addition to standard vasoactive agents. 
The iPGI2 group showed improved hemodynamics and only 14 patients (39%) had to return 
to CPB compared with all 30 patients (100%) in the NTG group. A trend towards a shorter 
length of stay in the ICU and reduced mortality was observed in the iPGI2 group, but the 
numbers were too small to achieve statistical significance. 
In order to avoid protamine reaction, heparinase I, a heparin degrading enzyme, was 
compared to protamine in a multicenter randomized controlled trial (Stafford-Smith et al., 
2005). The prevention of protamine-induced PH was also explored as a secondary end-
point. Heparinase I was not associated with a reduction in bleeding or reduction in the need 
for intervention in the treatment of PH. 
Lung diseases and/or hypoxia 
Low CO during cardiac surgery may affect the pulmonary circulation, potentially leading to 
hypoxia and worsen PH and RV failure. Thus, an acute perioperative low-output state 
should be reversed whenever possible before clinical manifestation of chronic 
hypoperfusion and organ dysfunction.  
Khan et al. (Khan et al., 2009) compared iNO to iPGI2 in 25 heart and lung transplant 
recipients with PH, refractory hypoxia, or RV dysfunction. Patients were randomized to 
iNO (20 ppm) or iPGI2 (20,000 ng/ml) as initial treatment in the operating room, followed by 
a crossover to the other agent after 6 hours. Both iNO and iPGI2 reduced PAP and central 
venous pressure (CVP), and improved cardiac index (CI) and mixed venous oxygen 
saturation on initiation of therapy. At the 6-hour crossover trial, there were no significant 
differences between groups in the reduction of PAP and CVP, and the improvement of CI 
and mixed venous oxygen saturation on initiation of therapy. Neither iNO nor iPGI2 
affected the oxygenation index or systemic blood pressure. 
In the case of chronic hypoxia, supplemental oxygen may be indicated to maintain arterial 
oxygen saturation at a level above 90 percent (Rubin & Rich, 1997). 
In the presence of lung disease, improvement of symptoms of PH may be obtained using 
basic therapy for PH, for instance, therapy for chronic obstructive pulmonary disease COPD 
and corticosteroids for interstitial lung disease. Antibiotic therapy for pneumonia as well as 
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elimination of ventilation/perfusion mismatch from and atelectasis can also help control 
PH. 
Chest drainage is required in patients with elevated intrathoracic pressure resulting from 
accumulated air or blood. However, chest closure may be associated with hemodynamic 
instability in patients requiring long procedures associated with prolonged CPB due to 
myocardial edema. The solution to this “thoracic compartment syndrome” consists in 
leaving the chest temporarily opened in order to reduce surrounding pressures until edema 
recedes. 
4.1.3 Post-capillary 
Left heart disease 
Left and right ventricular functions are interdependent. All LV function abnormalities 
induced by coronary artery disease, congestive heart failure, valvular heart disease, or 
systemic hypertension will influence RV function through ventricular interdependence 
mainly through an effect on the interventricular septum. Hence, a dilated LV and left atrium 
can shift the interatrial and interventricular septum and compress the right atrium and 
ventricule and reduce RV end-diastolic volume. 
Fernandes et al. (Fernandes et al., 2011) compared iNO to oxygen in 29 patients with PH 
after MVR. Treatments were initiated for 48 hours immediately after surgery. After 24 and 
48 hours, patients receiving iNO had a significantly greater increase in CI compared to 
patients receiving oxygen (p <0.0001). Pulmonary vascular resistance was also more 
significantly reduced in patients receiving iNO versus oxygen (p = 0.005) at 48 hours. 
Patients in the iNO group required less systemic vasoactive drugs and had a shorter ICU 
stay (p = 0.02).  
Kim et al. (Kim et al., 2010) compared the pulmonary vasodilation effect of combined 
preoperative oral sildenafil (50 mg) and beraprost (40 µg) (pulmonary vasodilators) to 
placebo in 50 patients scheduled for valvular heart surgery with PH (MPAP > 30 mmHg). 
Medication was initiated 15 min before the induction of anesthesia. The treatment group 
had a significantly lower systemic vascular resistance index (SVRI) at 60 min after 
medication. No other significant intergroup differences in hemodynamic variables were 
observed. In addition, significantly more patients in the treatment group required 
vasopressor therapy. In both groups, the PAP was significantly reduced by general 
anesthesia, and almost normalized after valvular heart surgery. The combination of 
preoperative oral sildenafil and beraprost treatment resulted in a loss of pulmonary 
selectivity, and did not provide any additional pulmonary vasodilation or benefits 
perioperatively. 
Wang et al. (Wang et al., 2009) investigated the postoperative effects of inhaled milrinone in 
48 patients with PH undergoing MVR. Patients were randomly assigned to receive inhaled 
milrinone (nebulized for 4 hours) or intravenous milrinone (control group bolus of 50 
microg/kg i.v. milrinone and then received a continuous milrinone infusion, 0.5 
microg/kg/min, for 4 hours) After milrinone administration, MPAP and PVR showed a 
comparable decrease in both groups. However, both mean MPAP and SVR in the inhaled 
group were significantly higher than in the control group. MPAP and PVR returned to 
baseline values 60 minutes after termination of milrinone inhalation. In addition, in the 
inhaled group, there was a reduction in intrapulmonary shunt fraction (Qs/Qt), with an 
improvement in arterial oxygen tension/fraction of inspired oxygen (PaO2/FiO2). 
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A study by Fattouch et al. (Fattouch et al., 2005) evaluated the effects of inhaled prostacyclin 
iPGI2 and iNO and compared them with those of conventional intravenous vasodilators (i.e. 
NTG and nitroprusside) in 58 patients with PH (PVR > 250 dyn·sec·cm-5 and MPAP > 25 
mmHg) suffering from severe mitral valve stenosis. Both drugs were administered by 
inhalation 5 min before weaning from CPB and continued in the ICU for up to 2 hours. 
Significant decreases in MPAP and PVR, as well as increases in CO and RVEF, were noted in 
both inhaled groups, which was not the case in the conventional group. Furthermore, 
patients in the inhaled groups showed easier separation from CPB, lower requirements for 
vasoactive drugs and shorter ICU and hospital lengths of stay. 
The same investigators also compared the same three strategies in 58 patients with mitral 
valve stenosis and elevated PVR (>200 dyn·sec·cm-5 and/or a transpulmonary gradient 
(MPAP-PAOP)>10 mmHg) after MVR (Fattouch et al., 2006). Intravenous nitroprusside (5–
15 g/min), iPGI2 (10 g/min) or iNO (20 ppm) were started immediately after patient 
admission to the ICU. Reduction in MPAP, PVR, and transpulmonary gradient were 
observed in all groups. Only iPGI2 was associated with a significant increase in stroke 
volume and CO. Administration of nitroprusside was associated with a reduction in SVR 
and occurrence of systemic hypotension. 
Feneck et al. (Feneck et al., 2001) compared milrinone to dobutamine in 120 patients with 
PAOP > 10 mmHg and low output syndrome after CBP (CO < 2 L/min/m²). In a subset of 
patients with PH (PVR > 200 dyn·sec·cm-5; MPAP > 25 mmHg), milrinone and dobutamine 
had similar effects in reducing PVR and increasing CI. However, milrinone was more 
effective in reducing PAOP and systemic vascular resistance (SVR). 
Finally, in 20 patients scheduled for mitral valve surgery with PH (MPAP > 25 mmHg), 
Hachenberg et al. (Hachenberg et al., 1997) explored the role of enoximone compared to a 
combination of NTG and dobutamine, given after induction of anesthesia and then restarted 
before the end of CPB. Only enoximone was associated with a decrease in MPAP and PVR. 
In the presence of PH secondary to LV failure, intra-aortic balloon counterpulsation may 
facilitate LV recovery.  
Patient-prosthesis mismatch (PPM) 
In the presence of prosthetic valve dysfunction after CPB, returning under CPB to correct 
the problem is considered the treatment of choice (Fig. 9).  
4.2 Experience at the Montreal Heart Institute 
At the Montreal Heart Institute, iPGI2 (Hache et al., 2001; Hache et al., 2003) and inhaled 
milrinone (Lamarche et al., 2005; Lamarche et al., 2007) are commonly administered to 
patients when PH and RV dysfunction occur before or after cardiac surgery. Oral sildenafil 
and iNO are also used in refractory cases in the ICU. Administration by inhalation has the 
advantage of selectively reaching well-ventilated regions of the lung and thus avoiding 
undesired decreases of systemic pressures. Future strategies may include the combination of 
currently available drugs and improvement of methods of administration for current drugs. 
5. Importance and impact of pulmonary hypertension in cardiac surgery 
Preoperative PH is associated with increased morbidity and mortality in cardiac surgery 
(Tuman et al., 1992; Tremblay et al., 1993; Reich et al., 1999; Bernstein & Parsonnet, 2000; 
Malouf et al., 2002). Therefore, awareness of PH is very important and its presence in any 
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form should be routinely reported to the surgeon and be evaluated in risk stratification 
models. Yet, this is not always the case, since only 4/19 risk stratification models in cardiac 
surgery include preoperative PH as a risk factor (Nilsson et al., 2006). Interestingly, PH is 
included in the EuroSCORE model which had the greatest discriminatory power over all 
other models. In a Swedish study including 4351 CABG patients, the receiver operating 
characteristics (ROC) of the EuroSCORE model was found to be 0.86 and 0.75 for the 30-day 
and one year mortality rates, respectively. 
Analysis performed using the Montreal Heart Institute anesthesia database in 1999 on a total 
of 1439 patients revealed a mean preoperative SPAP of 31±10 mmHg. PH was defined as 
SPAP > 30 mmHg and was observed in 605 patients (42%). The type of procedures 
performed in this subpopulation were mainly MVR (n=80, 40±14 mmHg), followed by 
combined CABG and valve procedures (n=126, 36±13 mmHg), multiple valve procedures 
(n=60, 36±16 mmHg) and heart transplantations (n=6, 36±14 mmHg). Severe PH defined as 
MAP/MPAP ratio < 2 was observed in 16 patients, who all experienced difficult separation 
from CPB, half of them required postoperative vasoactive support for more than 24 hours 
while 3 of them died (18.7%). 
Thus, PH present before, during or after the operation has an impact on survival mostly 
through its deleterious effect on right-sided heart function. The most dreaded consequence 
of PH is the increase in RV afterload and RV dysfunction which will be addressed herein. 
5.1 Right ventricular dysfunction 
Regardless of the underlying cause, uncontrolled PH leads to RV dysfunction. There is 
growing evidence showing that morbidity and mortality associated with PH depends on RV 
adaptation to the disease rather than on the absolute values of PAP (D'Alonzo et al., 1991; 
Yeo et al., 1998; Ramakrishna et al., 2005; Voelkel et al., 2006; Haddad et al., 2009). 
Furthermore, studies addressing hemodynamic variables and survival in idiopathic 
pulmonary arterial hypertension show that high mean Pra and low CO are consistently 
associated with poorer survival while PAP values are only moderately related to outcome 
(D'Alonzo et al., 1991; Chin et al., 2005). 
Many studies, in a variety of clinical settings, have demonstrated the importance of RV 
function in cardiac surgery (Table 3) (Haddad et al., 2009). Typical pathologies and 
treatments in these studies included high risk coronary or valvular heart disease, congenital 
heart disease, heart transplantation, patients requiring mechanical assist devices, and 
unstable patients postoperatively. However, most of the evidence supporting the 
importance of RV function pertains to retrospective and small prospective studies. 
Moreover, parameters of RV function have not yet been included in large scale models of 
risk stratification and thus, their incremental value to the Parsonnet Score and the 
EuroSCORE has not been well established (Bernstein & Parsonnet, 2000; Nashef et al., 2002; 
Shroyer et al., 2003; Ambler et al., 2005). A panel in 2006 from the National Institute of 
Health (NIH) has emphasized the importance of conducting research to better understand 
RV failure (Voelkel et al., 2006). 
5.1.1 Before the procedure 
In patients with severe aortic stenosis, Boldt et al. (Boldt et al., 1992) demonstrated that 
preoperative RV dysfunction was associated with increased requirements for postoperative 
inotropic support. 
www.intechopen.com
A Pathophysiological Approach to  
Understanding Pulmonary Hypertension in Cardiac Surgery 
 
295 
 
CAD: coronary artery disease; LVEF: left ventricular ejection fraction; LVAD: left ventricular assist 
device; RV: right ventricular; RVAD: right ventricular assist device; RVESV: right ventricular end-
systolic volume; RVEDV: right ventricular end-diastolic volume; RVEF: right ventricular ejection 
fraction; RVFAC: right ventricular fractional area change; RVMPI: right ventricular myocardial 
performance index; RVOTO: right ventricular outflow tract obstruction. (Haddad et al., 2009) 
Table 3. Prognostic Value of Right Ventricular Function in Cardiac Surgery (selected studies) 
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In a retrospective study involving patients undergoing mitral and mitral-aortic valvular 
surgery, Pinzani et al. (Pinzani et al., 1993) showed that preoperative RV failure was 
associated with increased perioperative mortality. Furthermore, in that study, postoperative 
RV failure was the most important independent predictor of late survival. 
In a small prospective study of 14 patients with severe non-ischemic mitral regurgitation 
presenting high risk descriptors (LV ejection fraction (LVEF)  45% or RVEF  20%), 
Wencker et al. (Wencker et al., 2000) found that preoperative RVEF  20% predicted late 
postoperative death.  
In a retrospective study of 41 patients undergoing non-emergent coronary artery bypass 
surgery, Maslow et al. (Maslow et al., 2002) have shown than RV dysfunction (right 
ventricular fractional area change (RVFAC)< 35%) in presence of severe LV dysfunction 
(LVEF ≤ 25%) was associated with an increased risk of postoperative morbidity and 
mortality. Furthermore, patients with RV dysfunction presented a higher prevalence of 
diabetes mellitus and renal disease, a higher incidence of postoperative support (inotropic 
or mechanical),  longer ICU and hospital  stays, as well as a decrease in short and long term 
survival. 
Experience at the Montreal Heart Institute 
Haddad et al. (Haddad et al., 2007) further assessed the value of RV function relative to 
other validated risk factors in open valvular heart surgery on 50 patients undergoing 
valvular surgery. Patients with RV myocardial performance index (RVMPI) < 50% (n=20) 
presented a significantly higher occurrence of circulatory failure (16/20 (80%) vs 6/30 (20%), 
p<0.0001) as well as a higher postoperative heart failure mortality (14/20 (74%) vs 3/30 
(10%), p<0.0001). In addition, multivariate analysis revealed RVMPI as the only 
independent predictor of heart failure and mortality among all other demographic, 
hemodynamic and echocardiographic variables (p<0.0001). 
5.1.2 After the procedure 
Right ventricular failure after CPB is associated with a mortality rate ranging from 44% to 
86% (Davila-Roman et al., 1995). The incidence of acute refractory RV failure ranges from 
0.04 to 0.1% after cardiac surgery. Acute refractory RV failure has also been reported in 2-3% 
patients after heart trasplantationand in 20-30% patients receiving support from a LV assist 
device with a reported initial salvage rate as low as 25-30% (Kaul & Fields, 2000). 
5.2 Treatment of right ventricular failure 
A proposed algorithm for the treatment of RV failure used at the Montreal Heart Instituteis 
summarised in Fig. 10. Assessment of RV function is performed visually when the chest is 
opened, by analysing RV pressure waveforms and using transesophageal echocardiography. 
Once RVOTO is ruled out, the etiology of RV systolic dysfunction is divided in two categories, 
either ischemic or not and with or without LV failure. If ischemia is suspected of causing either 
RV failure or bi-ventricular failure, treatments (medical and surgical) will be oriented towards 
the promotion of RV perfusion by means of thrombolysis, percutaneous transluminal coronary 
angioplasty, or CABG. Finally, pulmonary artery balloon pump, RV assist device or 
cavopulmonary diversion have also been described as potential treatments for severe RV 
dysfunction (Kaul & Fields, 2000). Otherwise, if a non-ischemic etiology is more likely or if no 
LV failure is present, treatments will rather be oriented towards an increase in contractility 
(inotropes) and a reduction in RV afterload (iNO, iPGI2, inhaled milrinone, oral sildenafil).  
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Fig. 10. Proposed approach in the treatment of right ventricular (RV) dysfunction. (LVOTO: 
left ventricular outflow tract obstruction; RCA: right coronary artery; RVOTO: right 
ventricular outflow tract obstruction; TEE: transesophageal echocardiography; TTE: 
transthoracic echocardiography). Presented at the 2011 Canadian Anesthesiologist Society 
Annual Meeting in Toronto, ON, Canada. 
Optimizing oxygenation and ventilation and ruling out other reversible causes of reduction 
in venous return such as reduction in MAP, increase in Pra and increase in resistance to 
venous return will also be important in managing these patients. 
6. Prevention of pulmonary hypertension in cardiac surgery 
6.1 Pharmacological 
Prevention of PH represents a promising strategy to prevent RV failure, its most important 
consequence after cardiac surgery. To date, very few studies have addressed this issue and 
one of the potential avenues constitutes the prevention of the pulmonary reperfusion 
syndrome. In this regard, both iPGI2 (Fortier et al., 2004) and inhaled milrinone (Lamarche et 
al., 2005) have been demonstrated to prevent CPB-induced endothelial dysfunction, in an 
animal model. A pilot randomized controlled trial (RCT) conducted by Hache et al. (Hache 
et al., 2003) in patients with preoperative PH concluded that iPGI2 was superior to placebo 
in reducing PH and was also associated with lower requirements for vasoactive support. 
A pilot RCT was conducted on the administration of inhaled milrinone before CPB in 21 
patients, all undergoing valvular surgeries (Denault et al., 2010b). Procedures consisted of 14 
complex surgeries and 5 reoperations. The study included a total of 8 males and 13 females 
with a mean age of 70±6.3 years old and a mean Parsonnet Score of 32±9. Inhaled milrinone 
(n=10) significantly reduced mean SPAP, which decreased from 66±20 mmHg (pre-CPB) to 
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46±20 mmHg (after CPB) (p<0.001). In contrast, SPAP remained unchanged in the control 
group (n=11) and no significant differences between groups were observed in decreased 
systemic arterial pressures. 
A retrospective study reporting the preliminary experience on the use of inhaled milrinone 
at the Montreal Heart Institute was conducted in 70 high risk patients with a mean 
Parsonnet Score of 27±14 (Bernstein & Parsonnet, 2000; Lamarche et al., 2007). Results were 
compared to those of a control group with similar baseline characteristics. In conclusion, the 
administration of inhaled milrinone prior to CPB (n=30) was associated with a lower chance 
of CPB re-initiation (9 vs 1; p=0.021) and lower postoperative PAP. Further studies (# 
NCT00819377) are underway to determine the efficacy of this approach. 
6.2 Non-pharmacological 
In addition to therapeutic approaches to the prevention of PH, the choice of type and size of 
aortic prosthetic valve may be a very important factor. As previously discussed, it has been 
shown that, if the EOA of the aortic valve is too small relative to body size, the so-called 
PPM, the intraoperative and long-term mortality will increase (Milano et al., 2001; Rao et al., 
2000; Pibarot & Dumesnil, 2000; Blais et al., 2003; Ruel et al., 2004; Pibarot & Dumesnil, 2006; 
Tasca et al., 2006; Kulik et al., 2006). Hence, prevention of PPM may contribute to reducing 
PH after cardiac surgery and facilitate separation from CPB. This includes strategies such as 
the implantation of a prosthesis with better performance (stentless bioprosthesis, new 
generation bileaflet mechanical valve, new generation supra-annular stented bioprosthetic 
valve) or enlargement of the aortic root (Fig. 9) in order to accommodate a larger prosthesis. 
On the other hand, some strategies used to prevent PPM are complex and may even increase 
the risk of difficult weaning from CPB extending the duration of the surgical procedure and 
consequently, CPB duration. Unfortunately, in some cases, the drawbacks of using 
alternative procedures may supercede the benefits of avoiding PPM. Therefore, the 
establishment of accurate criteria for a better assessment of the benefit-risk ratio with respect 
to the prevention of PPM is essential. In the case of mitral valve PPM, the best option would 
be to favor mitral valve repair rather than replacement. However, mitral valve repair may 
not be possible in a significant number of patients, which limits the options when compared 
to aortic valve replacement (Magne et al., 2007). 
7. Conclusion 
Pulmonary hypertension and its most dreaded consequence, RV dysfunction, are important 
mortality risk factors in cardiac surgery. Accordingly, all cardiac patients may benefit from 
early diagnosis and/or treatment prior to the surgical procedure. In patients with PH, 
further evaluation of potential alterations in the RV function would be relevant. Thus, future 
trials should prioritize in-depth exploration of preventive approaches in order to address 
the role of preemptive reduction of PH severity before cardiac surgery and to determine its 
impact on postoperative outcomes and survival improvement. 
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9. Abbreviations 
Ao   aorta 
AVR  aortic valve replacement  
CABG  coronary artery bypass graft 
CAD  coronary artery disease 
CI  cardiac index  
CO  cardiac output 
COPD   chronic obstructive pulmonary disease 
CPB  cardiopulmonary bypass 
CTEPH  chronic thromboembolic pulmonary hypertension 
CVP   central venous pressure 
D  diastolic 
DPAP  diastolic pulmonary arterial pressure 
EKG  electrocardiogram 
EOA  effective orifice area 
FRC  functional residual capacity 
ICU  intensive care unit  
iNO  inhaled nitric oxide 
iPGI2  inhaled prostacyclin 
LA  left atrium 
LV  left ventricle or left ventricular 
LVAD  left ventricular assist device 
LVEF  left ventricular ejection fraction 
LVOTO  left ventricular outflow tract obstruction 
MAP  mean arterial pressure 
MPAP  mean pulmonary artery pressure 
MVR  mitral valve replacement 
NIH  National Institutes of Health  
NO  nitric oxide 
NTG  nitroglycerin 
PaO2/FiO2  arterial oxygen tension/fraction of inspired oxygen 
PAOP  pulmonary artery occlusion pressure 
PAP   pulmonary artery pressure 
PCWP  pulmonary capillary wedge pressure 
PEEP  positive end-expiratory pressure 
PFO  patent foramen ovale 
PG  pressure gradient 
PGE1  prostaglandin E1 
PGI2  prostacyclin  
PH  pulmonary hypertension 
Pa  arterial pressure 
PCO2   partial pressure of carbon dioxide 
Ppa  pulmonary artery pressure 
PPM  patient-prosthesis mismatch 
Pra  right atrial pressure 
Prv  right ventricular pressure 
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PVR  pulmonary vascular resistance 
PVRI  indexed pulmonary vascular resistance  
Qs/Qt   intrapulmonary shunt fraction 
RA  right atrium 
RCA   right coronary artery 
RCT  randomized controlled trial 
ROC  receiver operating characteristics 
RPA  right pulmonary artery 
RV  right ventricle or right ventricular 
RVAD  right ventricular assist device 
RVEDV  right ventricular end-diastolic volume 
RVEF  right ventricular ejection fraction 
RVESV  right ventricular end-systolic volume 
RVFAC  right ventricular fractional area change 
RVMPI  right ventricular myocardial performance index 
RVOTO  right ventricular outflow tract obstruction 
RVSP  right ventricular systolic pressure 
S   systolic 
SAP  systemic arterial pressure 
SPAP  systolic pulmonary artery pressure 
SVR   systemic vascular resistance 
SVRI  indexed systemic vascular resistance 
TEE  transesophageal echocardiography 
TLC  total lung capacity 
Tr  tricuspid regurgitation 
TTE   transthoracic echocardiography 
UK  United Kingdom 
USA  United States of America 
V  velocity 
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